Novartis Ag
-
{
- All
- News
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
HCL Tech Wins Global Contract From Novartis
Under the deal, HCL will provide remote infrastructure management services to the Switzerland-based pharma company across its entire data centre landscape, covering more than 70 countries across six continents.
-
Ranbaxy's Generic Version of Novartis's Blood Pressure Drug Approved by US Regulator
The US Food and Drug Administration (FDA) said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
-
Ranbaxy up; Nod to Generic Version of Novartis Drug
Ranbaxy Laboratories rose 5.8 per cent in early trading after the US Food and Drug Administration (FDA) on Thursday said it has approved the company's generic version of Novartis AG's blood pressure drug Diovan.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Why Aurobindo Pharma Has Surged To A 30-Month High
Shares of Aurobindo Pharma Ltd. jumped nearly 4.7 percent after Novartis AG disclosed its subsidiary’s U.S. business results.
-
Aurobindo Pharma Acquires Sandoz’s Dermatology, Oral Solid Businesses In U.S. For $900 Million
The acquisition, which includes dermatology and oral solid businesses of Sandoz in the U.S., has been done in an all-cash basis.
-
Gene Therapy Was Hailed as a Revolution. Then Came the Bill
Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.
-
Gene Therapy Was Hailed as a Revolution. Then Came the Bill
Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.
-
Big Pharma’s Drug Studies Are Getting a NASA-Style Makeover
A third of development costs comes from clinical trials. Novartis wants to make them cheaper and faster.
-
Glaxo and Pfizer to Combine Consumer Health in Joint Venture
Glaxo will hold 68 percent of the venture, which will have combined sales of $12.7 billion.
-
Novartis Cuts 20% of Drug-Research Projects After Review
The company is also looking to expand in areas including cell, gene therapies to build on its purchase of drugmaker AveXis Inc.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
HCL Tech Wins Global Contract From Novartis
Under the deal, HCL will provide remote infrastructure management services to the Switzerland-based pharma company across its entire data centre landscape, covering more than 70 countries across six continents.
-
Ranbaxy's Generic Version of Novartis's Blood Pressure Drug Approved by US Regulator
The US Food and Drug Administration (FDA) said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
-
Ranbaxy up; Nod to Generic Version of Novartis Drug
Ranbaxy Laboratories rose 5.8 per cent in early trading after the US Food and Drug Administration (FDA) on Thursday said it has approved the company's generic version of Novartis AG's blood pressure drug Diovan.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Why Aurobindo Pharma Has Surged To A 30-Month High
Shares of Aurobindo Pharma Ltd. jumped nearly 4.7 percent after Novartis AG disclosed its subsidiary’s U.S. business results.
-
Aurobindo Pharma Acquires Sandoz’s Dermatology, Oral Solid Businesses In U.S. For $900 Million
The acquisition, which includes dermatology and oral solid businesses of Sandoz in the U.S., has been done in an all-cash basis.
-
Gene Therapy Was Hailed as a Revolution. Then Came the Bill
Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.
-
Gene Therapy Was Hailed as a Revolution. Then Came the Bill
Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.
-
Big Pharma’s Drug Studies Are Getting a NASA-Style Makeover
A third of development costs comes from clinical trials. Novartis wants to make them cheaper and faster.
-
Glaxo and Pfizer to Combine Consumer Health in Joint Venture
Glaxo will hold 68 percent of the venture, which will have combined sales of $12.7 billion.
-
Novartis Cuts 20% of Drug-Research Projects After Review
The company is also looking to expand in areas including cell, gene therapies to build on its purchase of drugmaker AveXis Inc.
